Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
MVA Smallpox vaccine · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| A | EXPERIMENTAL | Previously vaccinated for smallpox, 1x10-8 dose |
| B | EXPERIMENTAL | Smallpox vaccine naive, 1x10-8 dose |
| C | EXPERIMENTAL | Previous smallpox vaccination, 1x10-7 dose |
| D | EXPERIMENTAL | Smallpox vaccine naive, 1x10-7 dose |
| E | EXPERIMENTAL | Previous smallpox vaccination, 1x10-6 dose |
| F | EXPERIMENTAL | Smallpox vaccine naive, 1x10-6 dose |
| G | EXPERIMENTAL | Previous smallpox vaccination, placebo dose |
| H | EXPERIMENTAL | Smallpox vaccine naive, placebo dose |
| Name | Type | Description |
|---|---|---|
| MVA Smallpox vaccine | DRUG | Two 0.5mL subcutaneous injections, separated by 28 days |
| Placebo | DRUG | Two 0.5mL subcutaneous injections, separated by 28 days |
Inclusion Criteria: * subjects must be in good general health, checked on toxicity grading table. * for previously vaccinated subjects- must be between the ages of 33 and 55 with a previous vaccine more than 10 years ago. * for vaccine naive subjects- must be between the ages of 18 and 32, and have...
MVA Smallpox vaccine is an investigational vaccine being studied for the prevention of smallpox. It is currently in Phase 2 clinical development and has not been approved by regulatory authorities. The vaccine is being evaluated for its safety, tolerability, and immunogenicity in healthy adult volunteers.
MVA Smallpox vaccine is being developed by Sanofi, a multinational pharmaceutical company traded on the stock exchange under the ticker symbol SNY. The company is conducting clinical trials to evaluate the vaccine's potential for preventing smallpox.
MVA Smallpox vaccine is currently in Phase 2 clinical development. It is an investigational vaccine and has not yet received regulatory approval. The Phase 2 trial has been completed, and the vaccine remains under investigation for its safety and immunogenicity profile.
MVA Smallpox vaccine has been studied in one completed Phase 2 clinical trial registered as NCT00466245. This trial, titled 'Phase 2 Study of Safety, Tolerability, and Immunogenicity of Three Dose Levels of ACAM3000 Smallpox Vaccine,' enrolled 590 healthy adult volunteers aged 18 years and older.
Yes, MVA Smallpox vaccine is also known as ACAM3000. The Phase 2 clinical trial NCT00466245 refers to the vaccine as ACAM3000 Smallpox Vaccine, confirming that these names refer to the same investigational vaccine being developed by Sanofi.